Journal
Leukemia
Publication Date
8-28-2019
Volume
34
Issue
2
First Page
522
Last Page
532
Document Type
Open Access Publication
DOI
10.1038/s41375-019-0559-9
Rights and Permissions
Pott, C., Sehn, L.H., Belada, D. et al. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia 34, 522–532 (2020). doi.org/10.1038/s41375-019-0559-9 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Pott, Christiane; Sehn, Laurie H; Belada, David; Gribben, John; Hoster, Eva; Kahl, Brad; Kehden, Britta; Nicolas-Virelizier, Emmanuelle; Spielewoy, Nathalie; Fingerle-Rowson, Guenter; Harbron, Chris; Mundt, Kirsten; Wassner-Fritsch, Elisabeth; and Cheson, Bruce D, "MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial." Leukemia. 34, 2. 522 - 532. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/11750
Supplementary Information
